Cargando…
Multiregion single‐cell sequencing reveals the transcriptional landscape of the immune microenvironment of colorectal cancer
The tumor microenvironment is a complex ecosystem formed by distinct and interacting cell populations, and its composition is related to cancer prognosis and response to clinical treatment. In this study, we have taken the advantage of two single‐cell RNA sequencing technologies (Smart‐seq2 and DNBe...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775989/ https://www.ncbi.nlm.nih.gov/pubmed/33463049 http://dx.doi.org/10.1002/ctm2.253 |
Sumario: | The tumor microenvironment is a complex ecosystem formed by distinct and interacting cell populations, and its composition is related to cancer prognosis and response to clinical treatment. In this study, we have taken the advantage of two single‐cell RNA sequencing technologies (Smart‐seq2 and DNBelab C4) to generate an atlas of 15,115 immune and nonimmune cells from primary tumors and hepatic metastases of 18 colorectal cancer (CRC) patients. We observed extensive changes in the proportions and functional states of T cells and B cells in tumor tissues, compared to those of paired non‐tumor tissues. Importantly, we found that B cells from early CRC tumor were identified to be pre‐B like expressing tumor suppressors, whereas B cells from advanced CRC tumors tended to be developed into plasma cells. We also identified the association of IgA(+)IGLC2(+) plasma cells with poor CRC prognosis, and demonstrated a significant interaction between B‐cell and myeloid‐cell signaling, and found CCL8 (+) cycling B cells/CCR5(+) T‐cell interactions as a potential antitumoral mechanism in advanced CRC tumors. Our results provide deeper insights into the immune infiltration within CRC, and a new perspective for the future research in immunotherapies for CRC. |
---|